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SAMMANFATTNING 
En viktig orsak till tumörers uppkomst står att finna i en defekt hos cellcykelns reglering. En 
felaktig reglering av cellcykelns G1-fas tros vara en betydande orsak.  Anledningen till att G1-
fasen är extra känslig beror på att den styrs av många olika signaler på olika nivåer (såväl yttre 
faktorer som cykliner och cdks). I denna del av cellcykeln fattas viktiga beslut. G1-fasen kan 
delas upp i två delar, G1pm och G1ps. De innehåller varsin restriktionspunkt som måste passeras 
för att cellerna ska kunna gå in i S-fasen. Den första restriktionspunkten, R1, är beroende av 
tillväxtfaktorer och där bestäms om en cell ska fortsätta till S-fasen. Den kontrollerar således den 
cellcykel som innefattar DNA-replikation och mitos. Den andra restriktionspunkten, R2, som 
ligger i G1ps är bl a beroende av mängden näring och bestämmer när en cell ska gå vidare in i S-
fasen. Genom denna reglering justeras cellernas storlek så att dottercellerna är lika stora när de 
ska gå in i S-fasen. Tumörutveckling kan ske först när de transformerande cellerna har kunnat ta 
sig förbi både R1 och R2.  
G1-S gener kodar för flertalet proteiner som reglerar kaskadsignaler nedströms ner till kärnan där 
de slutligen kan verka som t.ex. transkriptionsfaktorer. Ras är ett av de viktigaste proteinerna som 
inte bara reglerar en utan flera intracellulära signalvägar som innehåller överlappande signaler. 
Dessa överlappande signaler är ett av de viktigaste kvarvarande vita fälten inom 
cancerforskningen.  
Men de andra faserna i cellcykeln kan också påverka tumörutvecklingen. Ett exempel som 
uppmärksammats på senare år är oupplösta och ofullständigt replikerade delar av arvsmassan i S-
fasen som fortsätter vidare till M-fasen utan att cellen stoppas.  
Det finns ännu många frågetecken som måste rätas ut. Sålunda arbetas det intensivt på att se hur 
onkogener kan tystas och därmed få defekta celler att gå i apoptos eller åldras. Dessa 
forskningslinjer kan innebära revolutionerande framsteg på vägen mot lösningen av cancerns 
gåta.      
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SUMMARY 
Tumour development occurs to a large extent because of dysregulation of the cell cycle. Of 
particular importance are defects occurring in the G1 phase. The reason why G1 is critical is 
because of the influence of several signals (external signals as well as cyclins and cdks) on this 
stage. The G1 phase can be divided into two parts, G1pm and G1ps. Each part has its “own” 
restriction point which needs to be passed in order to progress to S phase. The first restriction 
point, R1, is growth-factor dependent and decides if the cell progresses to S phase and hence also 
controls the chromosomal cell cycle i.e. DNA-replication and mitosis. The second restriction 
point, R2, located in G1ps is nutrient dependent and decides when the cell will progress to S 
phase.  By doing so it controls that the daughter cells are the same size before they enter S phase. 
Transformed cells need to overcome both R1 and R2 in order to induce tumour development.  
Transition from G1 to S is driven by genes that encode several proteins that regulate 
downstreaming signals. Ras is one of the most important proteins that not only regulate one 
downstream pathway but several overlapping pathways.  
Even though the main emphasis is on the G1 phase other phases can also affect the 
transformation process. For instance unsolved and incompletely replicated DNA in the S phase 
without a cell cycle stop before M phase is an area that has aroused recent interest.  
There are several issues that need further investigation. The findings of novel suppressor genes 
that inhibit oncogene expression and consequently induce apoptosis and cell senescence may 
contribute to the solving of the cancer riddle. 
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INTRODUCTION 
When a cell is preparing to undergo division, it has to pass several distinct phases in a tightly 
controlled fashion. Apart from what can be described as a “household control” procedure, namely 
the doubling of all its components, the key issue is whether the cell decides to progress towards 
mitosis or simply stop in the process (Mitchison, 1971).  
This stop/go control has aroused a great deal of interest and from a cell cycle point of view,  one 
specific phase, G1 phase, holds the key to a range of unresolved issues.  In this phase the cell can 
be influenced by different signals and stimuli that decide whether the cell should progress to the 
S phase and mitosis or leave the cell cycle and enter a reversible state of quiescence (G0) 
(Larsson et al., 1985a, 1985b).  
 
One of the hallmarks of transformation is that cells that should respond to suboptimal conditions 
by entering G0, instead progress towards S and mitosis. There are many explanations for this 
phenomenon including aberrant growth signals, the absence of inhibitors and negative control 
mechanisms. But the key issue remains how the stop/go switch in G1 is controlled and how it can 
be circumvented during transformation (Hanahan and Weinberg, 2011).  This paper aims to 
clarify hitherto unresolved issues as regards how the control mechanisms operate in G1 on a 
molecular level. 
 
MATERIAL AND METHODS 
This review is based on articles from the webpages “Web of science” and “PubMed”.  The search 
terms used for the literature search were: cell cycle, tumour, retinoblastoma, checkpoints, cyclin-
dependent kinase, CDK, cyclin D, cyclin E, G1 and G1/S. The search limitations that were used 
were language and sometimes also searching only on the authors.  
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LITERARY REVIEW 
 
Overview of the cell cycle 
The cell cycle consists of five different phases which all have to be completed in order to make 
the cell ready for division (Zetterberg and Killander, 1965) (fig. 1). Firstly a doubling of all 
subcomponents (e.g. RNA, protein and membrane lipids) needs to be completed and it takes 
place through the whole cell cycle. During the S phase the DNA replication as well as histone 
synthesis takes place, i.e. the doubling of the genome, and in the M phase first the nucleus and 
then the whole cell undergoes division. In between these phases there are two gaps called G1 and 
G2  (Howard and Pelc, 1951). Here, DNA damages and replication errors are repaired 
(Massagué, 2004). G2 is dedicated to the control of the replication machinery, the repair of 
eventual errors and to ensure that the cell is ready for mitosis. The G1 phase is particularly 
sensitive to signals that control cell cycle progression and ultimately the decision to divide. These 
signals can be positive (e.g. growth stimulatory signals) or negative (e.g. apoptotic or 
differentiation signals) and ultimately control the activity of different cyclin-dependent kinases 
(CDKs) that are the key operators that traverse stage specific cell cycle check points. 
Even if the cell cycle is defined as one cycle it can be divided in two parts, one chromosomal 
cycle where DNA replication and mitosis takes place, i.e. the doubling of the cellular 
components, and one growth cycle that involves cellular enlargement.  
In the G1 phase one critical point called “restriction point” (R) was discovered forty years ago. 
When the cell has passed through this checkpoint is it programmed to continue to the next 
division (Pardee, 1974).  
Moreover, G1 is the phase were normal cells under suboptimal conditions can decide to leave the 
cell cycle and pause in a reversible state of quiescence called G0. Tumour cells lack the capacity 
to enter G0 which enables them to undergo sustained proliferation and oncogenic transformation 
(Larsson et al., 1986, 1985a, 1985b; Massagué, 2004). In addition there are several substances 
and factors that can interfere with and eliminate functional cell cycle controls.   
Recently, several gene mutations that encode proteins that affect the G1 phase have been found to 
facilitate transformation and therefore point at this phase as especially important to investigate.   
Another interesting general theory is that cell damage induces both tumour development and cell 
aging (Hanahan and Weinberg, 2011). The difference is that normal cells enter senescence while 
tumour cells can overcome this barrier and continue to growth. In other words, protection against 
cell damage also protects the cell from aging and tumour development.  
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Critical checkpoints 
G1pm and G1ps  
The G1 phase can be divided into two parts, a constant post mitotic phase (G1pm) where the cell 
spends approximately 4 hours, and a more variable pre synthetic phase (G1ps) (Larsson et al., 
1985a) (fig. 2). Only when the cell is located in the G1pm it has the opportunity to leave the cell 
cycle and enter G0 in response to the absence or presence of different growth factors. Hence 
G1pm decides if a cell should continue through the cell cycle or not. 
Cells in the G1ps are already committed to DNA synthesis and are resistant to external growth 
factors. In contrast to G1pm, during G1ps the cell decides when it is going to enter the S phase and 
the duration in the G1ps varies between different cells (Larsson et al., 1985a). The rationale for 
this variability is that a small cell stays longer in the G1ps than a large cell, probably because the 
differences in size between cells must be adjusted before entering the S phase (Larsson et al., 
1985b). 
        Figure 1. Overview of the cell cycle 
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Gulliver (2013) has launched an interesting theory which aims to explain the decision whether a 
cell leaves G1pm to arrest or continues to G1ps. The decision requires a machinery that is 
influenced by several signals, each of them depending of each other like the layers of an onion. 
Inmost we have the transcribed and translated proteins encoded by the S genes. This depends on 
Rb phosphorylation status and E2F binding. That in turn depends on CDKs and other inhibitors 
in different phases of the cell cycle. Furthermore, this depends on growth factors and growth 
inhibitors also in the different phases that then depend on the presence of tumour suppressor and 
proto-oncogenes. Outhermost we have the influence of hormones. 
However, there is another theory that contradicts this “indecision theory” that predicts that the 
cell already has the machinery to promote cell cycle progression or arrest and just has to be 
driven by endogenous and exogenous factors. These factors (e.g. hormones or their imitators) 
regulate the machinery at different phases in the cell cycle. When the G1 and S phase are 
regulated they impact on the proliferation rate and cell enlargement. These factors can also 
modify the response to inhibition signals and facilitate sustained cell proliferation. Factors that 
regulate mitosis, e.g. oestrogen, are dependent on the endogenous hormone level in the body and 
that in turn depends on several things: the cells capacity for hormone production, ultimate 
microenvironment for hormone production, existence of receptors for specific hormones, higher 
expression of pro-mitogenic receptors than anti-mitogenic receptors and the age (Engström, 
2013). 
 
Figure 2. Regulation and duration of G1pm and G1ps  
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G1 to S transition 
To progress through the G1 phase the cell has to pass two restriction points (Foster et al., 2010). 
The first one called R1, sites at the end of the G1pm, controls the chromosomal cell cycle and is 
growth factor dependent.  When the cell passes this it is programmed to progress the cell cycle to 
the next mitosis. R1 corresponds to the original restriction point (R) (Pardee, 1974). Up to this 
point the cell could be exposed to a variety of stimuli, factors and components that affect the 
outcome and the cell can decide if it would like to arrest in the G0 phase. The second restriction 
point, R2, is located in the G1ps interval and is referred to as a “cell growth” checkpoint because 
it is dependent of nutritional supply. This “cell growth” checkpoint controls the cellular 
enlargement (growth cell cycle) and is regulated by mTOR (the mammalian target of rapamycin) 
and TGF-β (transforming growth factor β) and it is distinguished from R1 both in a temporal and 
genetic fashion (Foster et al., 2010). Moreover, tumour cells have lost their ability of adequately 
responding to the control mechanisms of both restriction points and progress through the cell 
cycle.  
According to classic findings, two growth factors with dual roles were used for an experimental 
approach to dissect different control points in the cell cycle. When a cell is arrested in G0 it is 
dependent on platelet-derived growth factor (PDGF) to re-enter the cell cycle, but for the 
following progression through G1ps it is dependent on insulin-like growth factor-1 (IGF1) 
(Zetterberg and Killander, 1965). Hence, it is reasonable to assume that PDGF increases levels of  
cyclin D whereas IGF1 increases PI3K and mTOR , thereby passing both of the checkpoints 
required for G1 to S transition (Glass, 2010).   
 
Cyclin-dependent kinases (CDKs) and cyclins are required for progression from G1 to S phase. 
Cyclin-dependent kinases form complexes with diverse cyclins that are specific for each phase of 
the cell cycle (fig. 3). It is above all the CDK1 (also called CDC28) that is regulated by cyclins 
and affect processes necessary for the cell cycle progression (Koltovaya, 2013).  
Although different cell types progress through the cell cycle in response to different signals, they 
all have one thing in common, they still have to activate CDKs (Massagué, 2004). 
Cyclin D and E are important for the progression through the G1 phase. Cyclin D peeks in the 
G1pm phase and cyclin E in the G1ps. Mitogenic stimuli increase the level of cyclin D which form 
a complex with CDK4/6. This complex hypophosphorylates Rb and after this cyclin D-dependant 
phase the cyclin E/CDK2 complex is activated. Cyclin E/CDK2 hyperphosphorylates and 
inactivates retinoblastoma (Rb) which makes it possible for the transcription factor E2F to be 
activated. E2F activates the transcription of cyclin E and other compounds (e.g. cyclin D, c-myc 
and DNA polymerase) that are needed for S phase progression and subsequent DNA replication 
(Massagué, 2004; Mayank et al., 2014). 
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The Cdk activity is low in the G0 and early G1 phase, thus Rb stays hypophosphorylated and 
binds E2F and transcription cannot be initiated (Mayank et al., 2014).   
Cyclin D levels peaks at R1(Harbour et al., 1999). 
Cyclin E forms a complex with CDK2. There are two types of cyclin E, Cyclin E1 and E2. In 
normal cells cyclin E1 peaks in the G1/S phase and is thereafter deregulated by the SCFFbw7 
ligase complex during the S and G2/M phase. In transformed cells this pulsatile expression is 
deregulated which results in high levels of cyclin E1 in the S phase that in turn leads to abnormal 
proliferation and genomic instability. Cyclin E2 is also uncontrolled in transformed cells and 
displays an enhanced and continuous expression during the S phase.  
Until recently, the knowledge was limited to the influence of cyclin E1 on tumourigenesis and 
thereby potential therapeutic routes were directed against cyclin E1 as well. Recent studies have 
shown that also cyclin E2 has a great impact because of the differences in regulation during the S 
phase between cyclins E1 and E2. The quantity of cyclin E1 mRNA and cyclin E2 mRNA differs 
in various cancer cells and are thought to be independently expressed (Caldon et al., 2013). 
Cyclin E is degraded through ubiquitin mediated proteolysis by an ubiquitin ligase called 
SCFFbw7 that binds to cyclin E. This binding depends on the phosphorylation of the site where 
degradation starts who is located at the C- and N-terminal of cyclin E. If the phosphorylation 
Figur 3. Cyclin, CDKs and its inhibitors 
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doesn´t begin at these sites cyclin E cannot be degraded, This  has been observed in tumour cells 
and promotes sustained proliferation (Minella et al., 2008). 
 
In normal cells there are CDK inhibitors that inhibit cyclin-cdk complexes when they are 
overexpressed (fig. 3). The CDK inhibitors p15, p16, p18 and p19 regulate cyclin D/CDK4/6 and 
p21, p27 and p57 inhibit cyclin E/CDK2 (Sherr and McCormick, 2002). Sherr and McCormick, 
(2002) also discuss that the cyclin E/CDK2 inhibitor p27 even affect cyclin D/CDK4/6. When 
cyclin D increases, p27 is sequestered which activate cyclin E/CDK2 and influences it to release 
p27 that in turn inhibit cyclin D/CDK4/6. However, there is one example of a theory where 
cyclin D does not need to sequester p27 to activate cyclin E. Instead a hypothetical feedback loop 
where cyclin E/CDK 2 phosphorylates p27 to make it more sensitive to ubiquitination and 
degradation by the proteasome at the same time as the complex also inactivates Rb and activates 
E2F which in turn increases cyclin E, has been proposed. In conclusion, the signals have reached 
full circle and progression towards the S phase has been enable (Martinsson et al., 2005). 
Another inhibitor of cyclin E/CDK 2 in G1ps is the transforming growth factor-β (TGF-β) which 
acts by elevating p27 (Massagué, 2004) (fig. 3). Hence TGF-β induces cell cycle arrest but only 
in the absence of myc since the upstream signals of myc, mTOR and PLD, inhibit TGF-β.  
Tumour promoters (e.g. phorbol esters) that induce progression through G1 and are activated by 
Ras require the inhibition of protein kinase Cδ (PKCδ) in order to progress to S phase. Thus, 
when PKCδ is activated the TGF-β mediated cell cycle arrest is operational (Lu et al., 1997) (fig. 
3). 
 
The tumour suppressor gene LIMD1 binds to Rb and prevents phosphorylation and inhibits E2F 
release. Therefore, cell cycle arrest and downregulation of S phase gene expression are induced, 
indicating the important role of LIMD1 as a regulator of the cell cycle.  
In the nucleus Rb is hypophosphorylated when it is stimulated by growth supressing signals. 
LIMD1 can bind to Rb, but LIMD1 also has the capability to move between the nucleus and 
cytoplasm, which points at an interesting theory that it is possible for cytoplasmic cell cycle 
specific signals to enter the nucleus and affect Rb (Mayank et al., 2014). However, further studies 
are required to understand the specific mechanisms concerning LIMD1s roll as an Rb- and cell 
cycle regulator especially if LIMD1 directly competes with cdks for the binding site. Only 50 % 
of the E2F suppression can be explained by LIMD1 binding to Rb. Thus further insights 
independent of Rb are needed to explain the other aspect of the E2F suppression.  
 
Protein phosphate 2A (PP2A) is a tumour suppressor that regulates the G1/S transition and is 
inhibited by Simian Virus 40 (SV40) small T antigen. The complex role of PP2A in 
tumourigenesis motivate further research about the requirement for transformation of cells, thus it 
is interesting to investigate mechanisms which compensate the lack of PP2A (Boehm et al., 
2005). 
 
M phase 
There is upcoming evidence that unsolved and incompletely replicated chromosomes in S phase 
remain unfinished when the cell progresses to the M phase. In the M phase these uncompleted 
DNA structures constitute a threat to the chromatid segregation and are thought to have an impact 
on human disease and aging. Moreover, it has been shown that the yeast Saccharomyces 
Cerevisiae can enter M phase before DNA-replication is completed (Mankouri et al., 2013).    
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There are four potential theories why cells enter M phase even though the S phase is not 
absolutely completed. Firstly, the S phase checkpoint cannot detect small regions of unreplicated 
DNA. Secondly, some regions of the genome with important structural functions (e.g. centromere 
and telomerase) are inherently difficult to replicate and segregate together with the rest of the 
DNA. Thus, cells have learned to deal with this inevitable situation and may also take advantage 
of it. Thirdly, it might be a fundamental aspect of a normal cell cycle progression and accomplish 
important biological functions.  
Fourthly, the M phase is considered more hazardous than the S phase and the inability of a total 
DNA replication may be a minor concern in the overall context. When the cell commits to 
mitosis in the G1 phase it will continue as quickly as possible to the M phase in order to 
minimise the risk for chromosomal defects. Moreover, cells are able to correct unresolved 
problems in the subsequent G1 phase.     
This theory arouses an interesting possibility that supressing mitotic defects by promoting mitotic 
devotion may result in healthy aging (Mankouri et al., 2013). 
 
 
Intracellular regulatory pathways 
To influence the cell with different stimuli, e.g growth factors, signals have to be transmitted by 
intracellular pathways from the extracellular area to the nucleus. Receptors are connecting the 
outside and inside of the cell. A major group of receptors are the type 1 growth factor receptors 
(ERBB/HER) that correspond to epidermal growth factor (EGF) stimuli and promote cell 
proliferation. Every EGF binds to a specific receptor. ERBB consists of an extracellular ligand-
binding domain that is connected with an intracellular tyrosine kinase domain (TK) that in turn 
affects a cascade of proteins in the intracellular pathway. To activate the TK and thus also getting 
the cascade effect, a ligand containing an EGF-like domain has to bind to the extracellular part of 
ERBB inducing a conformation change that facilitates dimerization between the receptors that in 
turn phosphorylate the downstreaming proteins. ERBBs affect the following downstreaming 
pathways: PI3K/Akt, Ras/MAPK, PLCγ1/PKC, STAT and Par6-atypical PKC, all of them 
influencing the cell by e.g inhibition of apoptosis, promoting proliferation, differentiation and 
angiogenesis. Mutations and oncogenetic precence in these pathways leads to dysregulation of 
these functions, hence tumour development is a common result (Wieduwilt and Moasser, 2008).  
 
Ras 
Ras transduces intracellular signals and is activated by a variety of growth factors (Westermarck 
and Hahn, 2008). Moreover, the Ras oncogene could activate mutations that are considered to be 
the first proliferation signal upon binding of a growth factor to its receptor. Transformed Ras 
elicitate intracellular signals in the absence of growth factor receptor activation and increase the 
cyclin D levels (Harbour et al., 1999). In conclusion, tumour transformation induced by Ras 
mutation is dependent on cyclin D.      
In normal cells when growth factors activate the Ras/Raf pathway a protein kinase cascade is 
induced that in turn increases cyclin D, myc and PTEN (phosphatase and tensin homolog)  
expression (Gille and Downward, 1999) (fig. 4).  In addition, the Ras/Raf pathway includes the 
protein kinase mTOR whose activity increases myc expression and cyclin D activity.   
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PTEN is a tumour suppressor that catalyses the reaction from phosphatidylinositol-3,4,5-tri-
phosphate (PIP3) to phosphatidylinositol-4,5-bis-phosphate (PIP2) and the reverse reaction is 
catalysed by PI-3-kinase (PI3K) (Yuan and Cantley, 2008, p. 2) (fig. 4). PI3K activity is common 
in human cancer and probably plays an important role in cell cycle progression since it increases 
PIP3 in the absence of PTEN (Manning and Cantley, 2007). Furthermore, PIP3 recruits pleckstrin 
homology (PH) domains e.g. phosphoinositide-dependent kinase 1 (PDK1) that in turn 
phosphorylates Akt which activates mTOR and induces G1 progression (Huang and Manning, 
2008).  
 
Amongst unresolved issues are the overlapping signals that alleviate G1pm to G1ps transition. Ras 
is the most important factor since it activates multiple downstreaming proteins and pathways e.g. 
Raf/MEK/MAP kinase pathway, PI3K, mTOR, Ral-GDS, PLD, cyclin D, c-myc. Therefore Ras 
should be able to dysregulate R1 and R2.  
Both Ras and myc are required for cell transformation. Ras activates myc expression and could 
not transform primary cells without myc.  
Cyclin D- null mice are resistant to transformation by Ras but not by myc. This indicates at the 
importance for Ras to activate downstreaming pathways.  
In addition, the most important target of Ras is the Raf/MEK/MAP pathway to stimulate cyclin D 
and G1pm to G1ps passage.  
 
Figur 4. Intracellular signaling by receptor activation of Ras 
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Myc 
C-myc plays an interesting and important role in cell cycle control because of its involvement in 
several different pathways that are influenced by external and internal signals. C-myc acts in 
concert with other factors on cell metabolism, proliferation, apoptosis and differentiation. For 
instance, c-myc increases the level of CDK 4, cyclin D, cyclin E and inhibits p27. 
Growing cells show a higher expression of c-myc than arrested cells. Tumour cells that are 
growing faster than normal cells express higher c-myc activity. In transformed cells c-myc 
promotes a circuit, it induces chromosomal translocation or gene amplification which in turn 
activates more c-myc expression (Dang, 1999).       
 
Src 
C-Src is a non-receptor tyrosine kinase which phosphorylates other proteins in order to induce 
proliferation, differentiation, angiogenesis and/or cell to cell adhesion. These multifaceted 
functions facilitate the promotion of metastatic changes (Yeatman, 2004). 
To activate different signals (e.g. proliferation and differentiation) Src has to interact with 
different factors e.g. cell surface receptors and steroid hormone receptors (Ishizawar and Parsons, 
2004). Src is activated by phosphorylation on the Tyr-416 residue and inhibited by 
phosphorylation on Tyr-527 which induces a binding to the SH2 domain making the kinase 
inactive (fig. 5).  Moreover elevated levels of c-Src expression are shown in many different 
tumour forms. 
 
Figure 5. Activation of Src 
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The mammalian target of rapamycin (mTOR) 
mTOR is a serine/threonine protein kinase which regulates important cell functions e.g. growth, 
survival, proliferation and transcription (Hay and Sonenberg, 2004). Hence, mTOR plays a major 
role in G1 phase. Moreover dysreglated mTOR is a common phenomenon observed in tumours.  
The mTOR is an important regulator of R2, thus also the transition through G1ps (Foster et al., 
2010) (cf above). mTOR is activated by amino acids and cell cycle arrest in G1ps is induced when 
the level of amino acids is low. Re-entry to the cell cycle at R2 when amino acids levels increase 
takes about two hours compared with 12 hours at the restriction point affected by growth factors 
(Zetterberg et al., 1995).   
One factor that changes the normal mTOR expression is Rheb – a GTPase. Rheb activates mTOR 
and originates from the Ras pathway, indicating that Ras and mTOR act in concert in 
transformation of normal cells (Sun et al., 2008). 
 
The mTOR inhibitor C-KβBA (3-cinnamoyl-11-keto-β-boswellic acid) is a new derivate 
indicating proapoptotic and antiproliferative activity on prostate cancer cell lines (PC-3). C-
KβBA acts cytotoxic and triggers apoptos in PC-3. PC-3 lacks PTEN which is a negative 
regulator of Akt and that, in turn, leads to activation of Akt (fig. 6). When PTEN is 
overexpressed in PC-3  it´s notable that PC-3 becomes less sensitive to C-KβBA proposing that 
the aim target of C-KβBA might be Act or downstream factors e.g. mTOR. Moreover, C-KβBA 
reduces cyclin D1 and thus makes the cell arresting in G1 phase (Morad et al., 2013).  
Next, the mTORs activity is regulated by ligands e.g. phosphatidic acid and rapamycin who bind 
to the part at mTOR called the FRB domain. It is showed that the C-KβBA also binds to the FRB 
domain and even harder than the ligands which allow competition between these (Morad et al., 
2013).  
Morad et al., (2013) also discuss the importace of finding a better mTOR inhibitory-therapy 
against cancer that can overcome the limitations of rapamycin. Rapamycin cannot prevent the 
upregulation of the MEK-ERK and PI3K/Akt signalling pathway as a result of the S6K1-
mediated feedback loop and the mTORC2 activation of Akt that in turn  result in prosurvival and 
proliferative signals that repress the effect of rapamycin (fig. 6). However, C-KβBA differs here 
in a positive way by lacking this activation of the Akt feedback loop. This probably depends on a 
partial inhibition of the mTORC2, a subunit of mTOR, or directly inhibition of Akt (fig. 6).  
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DISCUSSION 
The cell cycle concept has been around since mitosis in a growing cell population was 
discovered.  The discovery of the S-phase by Howard and Pelc (1951) was paramount for the 
understanding of the interphase, ie the time spent between two cell divisions. During the 1980:s a 
lot of interest was focussed on the variability in intermitotic time between individual cells 
(Brooks et al., 1980) as well as the regulatory steps in G1 (Larsson et al., 1985a, 1985b; Pardee, 
1974). Later research pointed at cyclins and cdk:s as key operators in the regulation of the cell 
cycle (Evans et al., 1983; Hartwell, 1967; Nurse et al., 1976). 
 
The cell cycle can be  regulated by a variety of external  factors, e.g. growth factors and cytokines 
normally operating through membrane bound receptors that transduces a signal to the cell nucleus 
(Massagué, 2004). The G1 phase is the most important phase where external signals play 
different roles in different subsections .Two restriction points R1 and R2 are cyclin regulated 
checkpoints that need to be passed in order to initiate DNA-synthesis in the S-phase.  
Transformation of normal cells to tumour cells therefore needs to dysregulate both R1 and R2, 
that in turn are regulated by cyclin D and cyclin E (Foster et al., 2010).  
Figur 6. Effects of C-KβBA in PC-3 cells 
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Once the signal has reached the interior of the cell membrane, Ras is activated. Ras is an example 
of a protein that induces overlapping signals and activates multiple downstreaming targets (Gille 
and Downward, 1999). Several of them result in activation of the mTOR pathway, thereby 
regulating R2 and consequently affect enlargement, survival, proliferation. Ras can also act 
through its most important target, the Raf/MEK/MAP kinase pathway and elevate cyclin D levels 
and in doing so, it also regulates R1.  
 
The normal defence against unwarranted progression through G1 is either differentiation, 
apoptosis (programmed cell death) or cell senescence (ageing) (Hanahan and Weinberg, 2011). 
When a cell is transformed, all these defence mechanisms are incapacitated. It is important to 
consider also antiapoptotic mechanisms as well as immortalisation as important hallmarks of 
transformation.   
 
A more fundamental issue is why mammalian cells are imperfect in the first place. It has been 
known for a long time that the time cells spend in interphase varies considerably. In this respect 
they differ from lower organisms, e.g. the slime mould Physarum polycephalum where nuclear 
division is more or less perfectly synchronised (Loidl and Sachsenmaier, 1982).  
However there are some interesting observations. When two daughter cells, i.e. siblings, were 
studied with respect to intermitotic time, it was found that their differences were smaller than 
when cells were compared at random (Brooks et al., 1980). Moreover, we now know that the cell 
possesses delicate machineries to repair defects in DNA-sequence and can correct mutations 
quite swiftly. We also know that the cell cycle machinery will be used at great length to ensure 
that the cell size homeostasis is upheld in a cell population (Zetterberg and Killander, 1965).     
 
Although G1 is considered to be the main regulatory phase and very much the target responsible 
for tumour transformation, dysregulation in other phases may also have an impact on tumour 
development. For instance, unresolved and incompletely replicated chromosomes in the S phase 
that progress to the M phase (Mankouri et al., 2013). 
 
In conclusion, there are still remaining issues including the enigmatic overlapping signals in G1 
but also black holes in our understanding of the other phases. An improved understanding of 
these key regulatory issues will facilitate the development of improved diagnostic features as well 
as novel therapies against cancer.   
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